These experiments examined the effects of the NMDA-receptor (NMDAr) antagonist MK801 on reacquisition and re-extinction of a conditioned fear that had been previously extinguished before injection of fibroblast growth factor-2 (FGF2) or vehicle. Recent findings have shown that relearning and re-extinction, unlike initial learning and extinction, do not depend on NMDAr activation. Three experiments demonstrated that FGF2 prevents the switch from NMDAr-dependent to NMDAr-independent reacquisition and re-extinction, suggesting that FGF2 may lead to the partial erasure of the original fear memory. These findings add to a growing body of work suggesting that FGF2 may be a novel pharmacological enhancer of exposure therapy for humans with anxiety disorders.